BIFIDO Co., Ltd. (KOSDAQ:238200)
South Korea · Delayed Price · Currency is KRW 2,880.00
-50.00 (-1.71%)
At close: Mar 31, 2026
BIFIDO Revenue
In the year 2025, BIFIDO had annual revenue of 19.68B KRW with 59.34% growth. BIFIDO had revenue of 4.83B in the quarter ending December 31, 2025, with 27.18% growth.
Revenue
19.68B
Revenue Growth
+59.34%
P/S Ratio
1.20
Revenue / Employee
237.10M
Employees
83
Market Cap
23.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.68B | 7.33B | 59.34% |
| Dec 31, 2024 | 12.35B | -6.28B | -33.72% |
| Dec 31, 2023 | 18.63B | 4.06B | 27.82% |
| Dec 31, 2022 | 14.58B | 2.46B | 20.32% |
| Dec 31, 2021 | 12.12B | -264.16M | -2.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 99.01B |
| GeneBioTech Co. ,Ltd | 90.79B |
| ChoA Pharmaceutical Co., LTD. | 59.31B |
| WooGene B&G | 54.76B |
| Seoul Pharma | 52.15B |
| Kwangdong Healthbio | 38.10B |
| Union Korea Pharm | 33.83B |
| Daesung Microbiological Labs. | 25.99B |